Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 10Completed 8Active not recruiting 7Withdrawn 4Recruiting 4Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 78Vincristine 69obinutuzumab 67Doxorubicin 66Prednisone 65Biopsy 64Magnetic Resonance Spectroscopy 62zanubrutinib 52Lenalidomide 52Dexamethasone 49Methotrexate 43Cytarabine 43blinatumomab 40acalabrutinib 37Immunotherapy, Adoptive 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21Mercaptopurine 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × R-CHOP protocol × Lymphoid × Clear all
NCT06549595 2026-05-20

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

AstraZeneca

Phase 3 Recruiting
1,018 enrolled
Lymphoid

Lymphoma, Follicular

NCT06517511 2026-02-12

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Sun Yat-sen University

Phase 2 Recruiting
42 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04566887 2025-02-18

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

University Health Network, Toronto

Phase 2 Recruiting
105 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT06647940 2024-10-22

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)

Sun Yat-sen University

Phase 2 Recruiting
39 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡